Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between
localized and poly-metastatic disease. Various retrospective studies and prospective clinical
trials are carrying out to validate whether patients with OMPCa could benefit from local
treatment for both primary and metastatic lesions. The investigators here to conduct a unique
clinical trial which OMPCa patients were confirmed by conventional imaging, and received a
long-term enhanced systemic therapy accompanied by tumor-directed therapy.